Clinical Trial Update: A First-in-human Study to Learn How Safe the Study Treatment BAY2862789 is, to Find the Best Dose, How it Affects the Body, What Maximum Amount Can be Given, How it Moves Into, Through and Out of the Body, and How it Acts on Different Tumors in Participants With Advanced Solid Tumors [Phase 1]

View source ↗

Summary

This first-in-human Phase 1 study of BAY2862789 aims to assess safety, determine the recommended dose, characterize pharmacokinetics/pharmacodynamics, and explo…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer
• Solid Tumors

Drugs mentioned

• BAY2862789

Snippet

Sponsor: Bayer | Conditions: Advanced Solid Tumors, Non-small Cell Lung Cancer | Phase 1 | Status: COMPLETED